As shown in Figure 7, three weeks post-treatment, compared to RA, the average signal and tumor volume were significantly suppressed by the co-administration of AZD3759, which was significantly reversed by the overexpression of JAK1 (**p < 0.01 vs. RA, ##p < 0.01 vs. AZD3759 + RA). Here, JAK1 is linked to neoplasm.